SEC Form SC 13D filed

2/16/21 5:21:56 PM ET

$EQ

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EQ alert in real time by email

SC 13D 1 tm216956d1_sc13d.htm SC 13D

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. )*

Equillium, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

29446K106

(CUSIP Number)

Decheng Capital Global Life Sciences Fund IV, L.P.

Ugland House, PO Box 309, Grand Cayman

KY1-1104, Cayman Islands

+1- 345-949-8066

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

February 5, 2021

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	NAME OF REPORTING PERSONS Decheng Capital Global Life Sciences Fund IV, L.P.
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ¨ (b) x
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (SEE INSTRUCTIONS) WC
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E):
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
Number of Shares Beneficially Owned by Each Reporting Person With		7	SOLE VOTING POWER 0
		8	SHARED VOTING POWER 4,271,423⁽¹⁾
		9	SOLE DISPOSITIVE POWER 0
		10	SOLE DISPOSITIVE POWER 4,271,423⁽¹⁾
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,271,423⁽¹⁾
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11: 14.7%⁽²⁾
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

⁽¹⁾ Consists of 3,285,710 shares of the Issuer’s Common Stock and 985,713 shares of the Issuer’s Common Stock issuable upon exercise of warrants, which are exercisable within 60 days of the date of this filing, held directly by Decheng Capital Global Life Sciences Fund IV, L.P. (“Fund IV”). Decheng Capital Management IV (Cayman), LLC (“General Partner IV”) is the general partner of Fund IV and Xiangmin Cui is the managing director of General Partner IV. Fund IV, General Partner IV and Dr. Cui may be deemed to share voting and dispositive power with respect to the shares held directly by Fund IV.

⁽²⁾ This percentage is calculated based upon 29,039,512 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s prospectus supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on February 4, 2021.

1.	NAME OF REPORTING PERSONS Decheng Capital Management IV (Cayman), LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ¨ (b) x
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (SEE INSTRUCTIONS) AF
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E):
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
Number of Shares Beneficially Owned by Each Reporting Person With		7	SOLE VOTING POWER 0
		8	SHARED VOTING POWER 4,271,423⁽³⁾
		9	SOLE DISPOSITIVE POWER 0
		10	SOLE DISPOSITIVE POWER 4,271,423⁽³⁾
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,271,423⁽³⁾
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11: 14.7%⁽⁴⁾
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

⁽³⁾ Consists of 3,285,710 shares of the Issuer’s Common Stock and 985,713 shares of the Issuer’s Common Stock issuable upon exercise of warrants, which are exercisable within 60 days of the date of this filing, held directly by Fund IV. General Partner IV is the general partner of Fund IV and Xiangmin Cui is the managing director of General Partner IV. Fund IV, General Partner IV and Dr. Cui may be deemed to share voting and dispositive power with respect to the shares held directly by Fund IV.

⁽⁴⁾ This percentage is calculated based upon 29,039,512 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s prospectus supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on February 4, 2021.

1.	NAME OF REPORTING PERSONS Decheng Capital Global Healthcare Fund (Master), LP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ¨ (b) x
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (SEE INSTRUCTIONS) WC
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E):
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
Number of Shares Beneficially Owned by Each Reporting Person With		7	SOLE VOTING POWER 0
		8	SHARED VOTING POWER 1,461,598⁽⁵⁾
		9	SOLE DISPOSITIVE POWER 0
		10	SOLE DISPOSITIVE POWER 1,461,598⁽⁵⁾
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,461,598 ⁽⁵⁾
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11: 5.0%⁽⁶⁾
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

⁽⁵⁾ Consists of 1,161,598 shares of the Issuer’s Common Stock and 300,000 shares of the Issuer’s Common Stock issuable upon exercise of warrants, which are exercisable within 60 days of the date of this filing, held directly by Decheng Capital Global Global Healthcare Fund (Master), LP (“Public Fund”). Decheng Capital Global Healthcare GP, LLC (“Public General Partner”) is the general partner of Public Fund and Xiangmin Cui is the managing director of Public General Partner. Public Fund, Public General Partner and Dr. Cui may be deemed to share voting and dispositive power with respect to the shares held directly by Public Fund.

⁽⁶⁾ This percentage is calculated based upon 29,039,512 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s prospectus supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on February 4, 2021.

1.	NAME OF REPORTING PERSONS Decheng Capital Global Healthcare GP, LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ¨ (b) x
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (SEE INSTRUCTIONS) AF
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E):
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
Number of Shares Beneficially Owned by Each Reporting Person With		7	SOLE VOTING POWER 0
		8	SHARED VOTING POWER 1,461,598⁽⁷⁾
		9	SOLE DISPOSITIVE POWER 0
		10	SOLE DISPOSITIVE POWER 1,461,598⁽⁷⁾
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,461,598⁽⁷⁾
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11: 5.0%⁽⁸⁾
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

⁽⁷⁾ Consists of 1,161,598 shares of the Issuer’s Common Stock and 300,000 shares of the Issuer’s Common Stock issuable upon exercise of warrants, which are exercisable within 60 days of the date of this filing, held directly by Public Fund. Public General Partner is the general partner of Public Fund and Xiangmin Cui is the managing director of Public General Partner. Public Fund, Public General Partner and Dr. Cui may be deemed to share voting and dispositive power with respect to the shares held directly by Public Fund.

⁽⁸⁾ This percentage is calculated based upon 29,039,512 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s prospectus supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on February 4, 2021.

1.	NAME OF REPORTING PERSONS Xiangmin Cui
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ¨ (b) x
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (SEE INSTRUCTIONS) AF
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E):
6.	CITIZENSHIP OR PLACE OF ORGANIZATION United States
Number of Shares Beneficially Owned by Each Reporting Person With		7	SOLE VOTING POWER 0
		8	SHARED VOTING POWER 5,733,021⁽⁹⁾
		9	SOLE DISPOSITIVE POWER 0
		10	SOLE DISPOSITIVE POWER 5,733,021⁽⁹⁾
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,733,021⁽⁹⁾
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11: 19.7%⁽¹⁰⁾
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

⁽⁹⁾ Consists of 3,285,710 shares of the Issuer’s Common Stock and 985,713 shares of the Issuer’s Common Stock issuable upon exercise of warrants, which are exercisable within 60 days of the date of this filing, held directly by Fund IV and Public Fund. General Partner IV is the general partner of Fund IV and Xiangmin Cui is the managing director of General Partner IV. Public General Partner is the general partner of Public Fund and Xiangmin Cui is the managing director of Public General Partner. Fund IV, General Partner IV, Public Fund, Public General Partner and Dr. Cui may be deemed to share voting and dispositive power with respect to the shares held directly by Fund IV and Public Fund.

⁽¹⁰⁾ This percentage is calculated based upon 29,039,512 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s prospectus supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on February 4, 2021.

Item 1.

Security and Issuer.

The class of equity securities to which this Schedule 13D relates is common stock, par value $0.0001 per share (“Common Stock”) of Equillium, Inc., a Delaware corporation (the “Issuer”). The principal executive offices of the Issuer are located at 2223 Avenida de la Playa, Suite 105, La Jolla, CA.

Item 2.

Identity and Background.

(a)

This Schedule 13D is filed by (i) Decheng Capital Global Life Sciences Fund IV, L.P. (“Fund IV”), a Cayman Islands exempted limited partnership, (ii) Decheng Capital Management IV (Cayman), LLC (“General Partner IV”), a Cayman Islands limited liability company (iii) Decheng Capital Global Healthcare Fund (Master), LP (“Public Fund”), a Cayman Islands exempted limited partnership, (iv) Decheng Capital Global Healthcare GP, LLC (“Public General Partner”), a Cayman Islands limited liability company and (v) Xiangmin Cui (“Dr. Cui”) (collectively, the “Reporting Persons”).

(b)

The address of the principal place of business of the Reporting Persons is Ugland House, PO Box 309, Grand Cayman, KY1-1104, Cayman Islands.

(c)

The principal business of both Fund IV and Public Fund is the venture capital investment business. The principal business of General Partner IV is acting as general partner of Fund IV. The principal business of Public General Partner is acting as general partner of Public Fund. The principal occupation of Dr. Cui is serving as the managing director of General Partner IV and Public General Partner.

(d)

During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)

During the last five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)

Fund IV and Public Fund are each a Cayman Islands exempted limited partnership, General Partner IV and Public General Partner is a Cayman Islands limited liability company and Dr. Cui is a citizen of the United States.

Item 3.

Source and Amount of Funds or Other Consideration.

Pursuant to the terms of that certain Securities Purchase Agreement by and among the Issuer, Fund IV, and Public Fund (collectively, the “Investors”), dated February 3, 2021 (the “Securities Purchase Agreement”), the Investors purchased in a private placement 4,285,710 units representing (i) 4,285,710 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and (ii) warrants to purchase an additional 1,285,713 shares of Common Stock for $7.00 per unit (each unit consisting of one share of Common Stock and a warrant to purchase 0.3 of a share of Common Stock) (the “Financing”). The Financing closed on February 5, 2021. The aggregate purchase price of the Shares and the Warrants acquired by the Investors was $29,999,970.00.

The funds used by Fund IV and Public Fund to acquire the securities described above were obtained from working capital contributed by their partners and members.

Item 4.

Purpose of Transaction.

Fund IV and Public Fund each agreed to purchase the Shares and the Warrants described herein for investment purposes with the aim of increasing the value of the Issuer and its investment in the Issuer. In connection with the Financing, and as a condition thereof, Dr. Yu (Katherine) Xu, Ph.D. joined the Board on February 3, 2021 as an appointee of the Investors. As a director of the Issuer, Dr. Yu may have influence over the corporate activities of the Issuer, including activities which may relate to the transactions described in clauses (a) through (j) set forth below in this Item 4.

Except as set forth herein and except that the Reporting Persons or any of their affiliates may, from time to time or at any time, subject to market conditions and other factors, purchase additional shares of Common Stock of the Issuer in the open market, in privately negotiated transactions or otherwise, or sell at any time all or a portion of the common stock of the Issuer now owned or hereafter acquired by them in the open market, in privately negotiated transactions or otherwise, as of the date of this Schedule 13D, none of the Reporting Persons has any present plans which relate to or would result in:

(a)

The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

(b)

An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

(c)

A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

(d)

Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

(e)

Any material change in the present capitalization or dividend policy of the Issuer;

(f)

Any other material change in the Issuer's business or corporate structure including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940;

(g)

Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

(h)

Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

(i)

A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

(j)

Any action similar to any of those enumerated above.

Item 5.

Interest in Securities of the Issuer.

(a)

As of the date hereof, Fund IV is the record owner of 4,271,423 shares of Common Stock, including 985,713 shares of Common Stock issuable within 60 days of the date of this filing upon the exercise of Warrants. Fund IV is controlled by General Partner IV and Dr. Cui. As of the date hereof, Public Fund is the record owner of 1,461,598 shares of Common Stock, including 300,000 shares of Common Stock issuable within 60 days of the date of this filing upon the exercise of Warrants. Public Fund is controlled by Public General Partner and Dr. Cui. As such, each of the Reporting Persons may be deemed to share voting and dispositive power over the shares held by Fund IV and Public Fund. As such, General Partner IV, Public General Partner and Dr. Cui may be deemed to beneficially own the shares held directly by Fund IV and Public Fund.

(b)

	Number of Shares of Common Stock
	Power to Vote or Direct the Vote				Power to Dispose or Direct the Disposition
Reporting Person	Sole		Shared		Sole		Shared
Decheng Capital Global Life Sciences Fund IV, L.P		0		4,271,423		0		4,271,423
Decheng Capital Management IV (Cayman), LLC		0		4,271,423		0		4,271,423
Decheng Capital Global Global Healthcare Fund (Master), LP		0		1,461,598		0		1,461,598
Decheng Capital Global Healthcare GP, LLC		0		1,461,598		0		1,461,598
Xiangmin Cui		0		5,733,021		0		5,733,021

(c)

The information provided and incorporated by reference in Item 3 is hereby incorporated by reference. There were no other transactions in the Common Stock by the Reporting Persons in the 60 days prior to the date of the event which requires the filing of this Schedule 13D.

(d)

No other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock beneficially owned by the Reporting Persons.

(e)

Not applicable.

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Warrants

In the Financing, the Investors received Warrants to purchase an aggregate of 1,285,713 shares of Common Stock at an exercise price of $14.00 per share, subject to adjustments as provided under the terms of the Warrants. The Warrants are exercisable at any time and expire on February 5, 2026. The foregoing description of the Warrants is qualified in its entirety by reference to the form of Warrant, which is filed as an exhibit to this Schedule and is incorporated by reference herein.

Board

Under the Securities Purchase Agreement, the Investors are entitled to nominate one member of the Issuer’s Board (the “Decheng Director”), and the Issuer will take all necessary actions to nominate such director at each meeting of stockholders where such nominee is up for re-election. The initial Decheng Director is Dr. Yu. The foregoing description of the board representation rights contained in the Securities Purchase Agreement is intended as a summary only and is qualified in its entirety by reference to the Securities Purchase Agreement, which is filed as an exhibit to this Schedule 13D and incorporated herein.

Item 7.

Material to Be Filed as Exhibits.

Purchase Agreement, dated February 3, 2021, by and among the Company and the Purchasers, (Incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2021).

Form of Warrant (Incorporated by reference to Exhibit 4.1 to the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2021).

Agreement regarding filing of joint Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 15, 2021

Decheng Capital Global Life Sciences Fund IV, L.P.

By its General Partner

Decheng Capital Management IV (Cayman), LLC

By:	/s/ Xiangmin Cui
Name:	Xiangmin Cui
Title:	Managing Director

Decheng Capital Management IV (Cayman), LLC

By:	/s/ Xiangmin Cui
Name:	Xiangmin Cui
Title:	Managing Director

Decheng Capital Global Global Healthcare Fund (Master), LP

By its General Partner

Decheng Capital Global Healthcare GP, LLC

By:	/s/ Xiangmin Cui
Name:	Xiangmin Cui
Title:	Managing Director

Decheng Capital Global Healthcare GP, LLC

By:	/s/ Xiangmin Cui
Name:	Xiangmin Cui
Title:	Managing Director

Xiangmin Cui

By:

/s/ Xiangmin Cui

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: - Intentional misstatements or omissions of fact
constitute Federal criminal violations (See 18 U.S.C. 1001)

EXHIBIT C

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13D is being filed on behalf of each of the undersigned.

Dated: February 15, 2019

Decheng Capital Global Life Sciences Fund IV, L.P.

By its General Partner

Decheng Capital Management IV (Cayman), LLC

By:	/s/ Xiangmin Cui
Name:	Xiangmin Cui
Title:	Managing Director

Decheng Capital Management IV (Cayman), LLC

By:	/s/ Xiangmin Cui
Name:	Xiangmin Cui
Title:	Managing Director

Decheng Capital Global Global Healthcare Fund (Master), LP

By its General Partner

Decheng Capital Global Healthcare GP, LLC

By:	/s/ Xiangmin Cui
Name:	Xiangmin Cui
Title:	Managing Director

Decheng Capital Global Healthcare GP, LLC

By:	/s/ Xiangmin Cui
Name:	Xiangmin Cui
Title:	Managing Director

Xiangmin Cui

By:

/s/ Xiangmin Cui

Get the next $EQ alert in real time by email

Date	Price Target	Rating	Analyst
1/5/2022	$18.00 → $14.00	Outperform	SVB Leerink
10/29/2021	$12.00	Buy	Stifel
9/15/2021	$14.00	Overweight	Cantor Fitzgerald

SEC Form SC 13D filed

Chat with this insight

Recent Analyst Ratings for $EQ

$EQ Leadership Updates

Live Leadership Updates

Equillium to be included in the Russell Microcap® Index

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Equillium Announces Appointment of Barbara Troupin to Board of Directors

$EQ SEC Filings

SEC Form 8-K filed by Equillium Inc.

SEC Form 10-Q filed by Equillium Inc.

Equillium Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$EQ Large Ownership Changes

This live feed shows all institutional transactions in real time.

$EQ Press Releases

Fastest customizable press release news feed in the world

$EQ Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

SEC Form SC 13G filed by Equillium Inc.

SEC Form SC 13G/A filed by Equillium Inc. (Amendment)

SEC Form SC 13G/A filed by Equillium Inc. (Amendment)

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

SVB Leerink reiterated coverage on Equillium with a new price target

Stifel resumed coverage on Equillium with a new price target

Cantor Fitzgerald initiated coverage on Equillium with a new price target

$EQ Market Insights

Live Market Insights

Equillium Inc: Receives Nasdaq Notice Of Non-Compliance With Listing Rule 5550(A)(2) On July 19, 2024

Equillium Announces Q2 2024 Ending Cash, Cash Equivalents, And Short-Term Investments Total Approximately $33.3M, Up $1.0M From Q1; Increase Driven By $2.7M Australian Tax Credit For 2023 R&D Expenses

Equillium To Be Included In The Russell Microcap Index, Effective At The Open Of Equity Markets On Monday, July 1

$EQ Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$EQ Financials

Live finance-specific insights

Sr. Vice President and COO Zedelmayer Christine sold $18,750 worth of shares (15,000 units at $1.25), decreasing direct ownership by 10% to 135,246 units (SEC Form 4)

Principal Accounting Officer Tom Penny sold $4,398 worth of shares (3,518 units at $1.25), decreasing direct ownership by 35% to 6,533 units (SEC Form 4)

Chief Financial Officer Keyes Jason A sold $8,100 worth of shares (10,000 units at $0.81) (SEC Form 4)

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis

Recent Analyst Ratings for
$EQ

$EQ
Leadership Updates

$EQ
SEC Filings

$EQ
Large Ownership Changes

$EQ
Press Releases

$EQ
Analyst Ratings

$EQ
Market Insights

$EQ
Insider Trading

$EQ
Financials